Inbiomotion

About:

Inbiomotion is a personalized medicine company developing biomarkers that can predict bone metastasis in cancers.

Website: http://inbiomotion.com

Top Investors: EASME - EU Executive Agency for SMEs, ICF Capital, Ysios Capital, Alta Life Sciences, Fundación Vila Casas

Description:

Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions. Inbiomotion's unique diagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.